^
Association details:
Biomarker:NRAS G13R
Cancer:Melanoma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Excerpt:
The MEK1E203K and N-RASG13R mutations were identified in Prog tumors derived from patients 1 and 24, respectively (Supplementary Table S2) and were also detected in our targeted screen (Table 1)....only one of the two phenotypically distinct nodules within a vemurafenib-resistant tumor (patient 24) contained mutant N-RAS. Similarly, two subclonal N-RAS mutations were identified within a single vemurafenib-resistant metastasis (42), and multiple mechanisms of resistance were detected, but did not coexist, in single-cell derived dabrafenib-resistant melanoma clone.
DOI:
10.1158/1078-0432.CCR-13-3122